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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
botulinum toxin A is an effective treatment for children who have lower limb spasticity from
cerebral palsy.
STUDY DESIGN: The study by Carraro et al was a randomized double-blind clinical trial
done in 2015.6The study done by Kim et al was a randomized, double-blind controlled
clinical trial done in 2010.7 The study by Py et al was a clinical trial done in 2005-2006.8
DATA SOURCES: Data sources obtained for this review were articles published in peerreviewed journals found using PubMed Database.
OUTCOMES MEASURED: The outcome measured the effectiveness of Botox and Botox
verse Xeomin and Neuronox, as well as the improvement of Gross Motor function with the use
of Botox and Neuronox.
RESULTS: The study Carraro et al showed that incobotulinum toxin A (Xeomin) was just as
effective for the treatment of spasticity from cerebral palsy, as onabotulinum toxin A
(Botox).6The study by Kim et al, showed the Neuronox was just as effective as Botox.7Lastly,
the study by Py et al, provided clear evidence that onabotulinum toxin A (Botox), was an
effective treatment of spastic gait in cerebral palsy in the first place.8
CONCLUSIONS: The results of the studies showed at Xeomin, Neuronox, and Botox all have
similar results efficacy for the treatment of lower limb spasticity in children with cerebral palsy.
KEY WORDS: Cerebral Palsy; Spastic Gait; Botox
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INTRODUCTION
Cerebral palsy is a term that is nonspecific and used to describe a chronic, static impairment
of muscle tone, strength, coordination, or movements due to some type of cerebral insult or injury
before birth, during delivery, or in the perinatal period.1This condition is caused by abnormal
development of the brain or damage to the developing brain that affects the child’s ability to
control his or her muscles.2 Even though the concept of how this condition develops is known, the
exact cause of the disease is unknown. Cerebral palsy effects 1.5 to 4 of every 1,000 live births,
making cerebral palsy the most common motor disability in childhood.2 It is estimated that the
average cost of healthcare of a patient with cerebral palsy in their lifetime is $910,000.2 In 2000, it
was estimated that the combined lifetime costs for all patients with cerebral palsy totaled $11.5
billion in direct and indirect costs of having this condition.2 Of course, severity manifestations and
prognosis vary substantially from patient to patient with cerebral palsy.1
The most common form of cerebral palsy that accounts for 75% of cases involve spasticity
of the limbs.1 Once the diagnosis is classified as spastic cerebral palsy, there is a term attached to
the diagnosis that is used to describe the specific patients degree of spasticity. The term
monoplegia describes the patients with one limb affected.1 Hemiplegia describes patients that
have an arm and leg that are affected on the same side of the body, but the arm is more affected
than the leg.1 Paraplegia describes patients that have both legs affected and both arms unaffected.1
The last descriptive term used to describe patients with spastic cerebral palsy s quadriplegia,
which describes a cases where all four limbs are affected equally.1
The next most common form of cerebral palsy is ataxia, which accounts for around 15% of
cases.1The most common way the ataxia effects the patients is in fine coordinated movement of
the upper extremities, but may also effect the lower extremities and the trunk. Lastly, persistent
hypotonia without spasticity accounts for 1% of cases.1
Many different neurologic deficits tend to occur in the presence of motor deficits that are
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caused by cerebral palsy.1 Seizures occur in up to 50% of these patients, mild retardation in 26%
and severe retardation in up to 27%.1 Many different other disorders coexist in theses patients in
varying degrees and combonations.1 Some commonly seen disorders are of language, speech,
vision, hearing and sensory perception.1
The most common finding on physical exam are those of spasticity, hyperreflexia, ataxia,
and involuntary movements.2 Microcephaly is often present.1The patients with spastic hemiplegia
type of cerebral palsy can present with the affected arm and leg may be smaller and shorter than the
unaffected limbs.1
Cerebral palsy is a clinical diagnostic term that is used to describe patients with similar
symptoms due to a cerebral insult around birth.2 The use of laboratory and imaging tests
depends on each patients presenting symptoms, as there is no one diagnostic test for cerebral
palsy.1 One of the more common imaging tests done is an MRI. The MRI scan may be helpful
in seeing the full extent of the cerebral injury and can suggest an etiology for the
condition.1Interest is growing for genetic and metabolic testing, which can be useful to figure
out a cause in combination with the history and MRI findings.1There are two common findings
in a newborn that help diagnose cerebral palsy, even though they are not diagnostic.3 The first
being the Apgar score given at 1 and 5 minutes after delivery. It has been shown that when the
5-minute Apgar score is less than 3 the risk of neurological sequelae, such as cerebral palsy is
increased substaintially.4Another finding in the newborn period that can support the diagnosis
of cerebral palsy is umbilical cord blood pH less than 7 and a base deficit greater or equal to
12.3 These findings within the umbilical cord are objective evidence for metabolic acidosis and
the worse the acidosis, the more risk that patient has for cerebral palsy.3
The treatment of cerebral palsy has been studied and is an area that is actively
researched. All the treatments for cerebral palsy are directed at assisting the patient to attain
maximum neurologic functioning with appropriate physical, occupational, and speech therapy as
well as medications for spasticity and seizures.1 The current treatment for spastic cerebral palsy
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includes oral antispastic drugs, intrathecal baclofen, surgical treatment such as selective dorsal
rhizotomy and deep brain stimulation, and botulinum toxin injection.
The efficacy regarding the use of botulinum toxin injection to increase function in
patients with lower limb spasticity from cerebral palsy is a hot topic among healthcare
providers. Botulinum neurotoxins are classified into seven categories: A, B, C1, D, E, F, and
G.5The difference between the categories is their biosynthesis, size, cellular sites of action,
binding kinetics, duration of effect and stability.5 The two types of botulinum neurotoxin that
are currently commercially available are serotypes A and B. The mechanism of action of
botulinum is first the toxin enters the nerves by binding to surface protein receptors and
undergoing endocytosis into internalized vesicles.5 Then, the light chain is released into the
nerve cytosol and the SNARE (soluble N- ethylmaleimdie-sensitive factor attachment
protein receptor) protein complex is cleaved to inhibit exocytosis of the neurotransmitters
such as acetylcholine.5The receptor for all types of botulinum toxin A is SV2/SNAP-25.5The
end result is a chemodenervation of cholinergic neurons, which leads to a localized absence
of skeletal muscle activity.5Eventually due to nerve sprouts of the chemodenervated nerves
there is reestablished chemical contact with their targets and muscles resume activity.5The
brand name of a specific botulinum toxin is Botox and it is a serotype botulinum toxin A.5
Botox is the most commonly used botulinum toxin, as it is the one that has been studied most
thoroughly.5There are many next brands of botulinum toxin that are becoming available on
the market for use, but there are few studies that show if they are as effective as Botox.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not botulinum
toxins, besides Botox are effective for treating children who have lower limb spasticity from
cerebral palsy. The hypothesis about the objective is that the use of other botulinum toxins are
also an effective treatment option besides Botox, of lower limb spasticity in children with
cerebral palsy.
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METHODS
The studies that were selected during the construction of this EBM review were two randomized
controlled trials and one clinical trial.6,7,8 The population studied in the trials included children with
cerebral palsy under the age of 18 and have lower limb spasticity. The interventions in each study
involved administration of a brand of a serotype A of botulinum toxin. The first study by Py and et
al, studied the effectiveness of Botox.8 In the study done by Carraro and et al, the effectiveness of
Xeomin (a type of botulinum toxin A) verse Botox (a type of botulinum toxin A) was studied.6 The
study done by Kim and et al compared the effectiveness of Neuronox (a type of botulinum toxin A)
and Botox.7 Neuronox is not currently FDA approved for use of any condition currently in the
United States.5The outcome measured that is of particular interest to this EBM review was the
number of adverse effects and the improvement of functional ability of the patient. For
clarification, each botulinum toxin in this EBM review, is in the serotype of A, but they each have
slight individual differences.5A few notable differences between the products are the process by
which the product is made, the complex molecular weight uniformity, and the stabilization
solubilization pH.5 The differences are shown in the chart below:
Nonproprietary name (FDA)
Process
Complex mw uniformity
Stabilization/ solubilization pH

Botox
Onabotulinum toxin A
Crystallization
-900kD homogenous
Vacuum dried
normal saline
-7

Xeomin
Incobotulinum toxin A
Chromatography
-150kD
Vacuum dried
normal saline
-7.4

Neuronox
Not FDA approved
Chromatography
-150kD
lyophilization
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Using PubMed databases, three studies were selected. Keywords used in the literature search
were “cerebral palsy”, spastic gait”, and “Botox”. All articles were published in English in peerreviewed journals and were selected based on significance and application, as well as the condition
that outcomes measured were patient oriented outcomes (POEMS). Inclusion and exclusion criteria
were similar across all three articles. Inclusion criteria involved studies that were randomized
control trials/clinical trials, published after 2011, participations were children with cerebral palsy
spastic subtype under the age of 18. Patients were excluded from the study if they had a history of
anaphylactic reactions to BoNT-A, a bleeding tendency, or a history of treatment with
anticoagulants, aminoglycosides, muscle relaxants, parasympathetic antagonists, or dopaminergic.
Individuals who have previously undergone surgery on the muscles or ligaments of the lower
extremities who had fixed contracture of the lower limb joints or who exhibited severe athetoid
movements were also excluded. Table 1 demonstrates the demographics of the studies included in
this EBM review. The statistic used in all the studies was the p-value.
Table 1: Demographics & Characteristics of included studies
Study
Carraro3

Type
RCT

#pts
35

Age
3-18
years
old

Inclusion Criteria
Patients had to have a
diagnosis of spastic
diplegia, hemiplegia or
quadriplegia due to CP,
as verified by history,
clinical/instrumental
examination and
neuroimaging findings;
they were between 3
and 18 year of age.

Exclusion Criteria
Subjects were excluded from the
study if was present one of the
following criteria: peripheral nervous
system disorders/ myopathies;
previous treatments for spasticity
other than BTX-A to the lower limbs
(<1 years); previous orthopedic
surgery to lower extremities; bone or
joint deformities and fixed
contractures; medications that could
have had an impact on the study
findings (es. Intrathecal baclofen,
benzodiazepines, muscle relaxant).

W/D
0

Interventions
Botox and
incobotulinum

Kim4

RCT

119

2- 10
years
old

Childrenwho hada
diagnosisof CP, were
aged between2 and 10
years, and who were
classified as Gross
Motor Function
Classification System
(GMFCS) level I, II, or
III were eligible for
participation inthe
study. They hadto
show tiptoeing gait asa
resultofspasticcalf
musclesandbeableto
receivephysio- therapy
followinga
standardized protocol
for lowerlimb
spasticity. The
participants were
recruited from
individuals who visited
the outpatient
departments of the

Patients were excluded from the study if they
had a history of anaphylactic reactions to
BoNT-A, a bleeding tendency, or a history
of treatment with anticoagulants,
aminoglycosides, muscle relaxants,
parasympathetic antagonists, or
dopaminergic. Individuals who have
previously undergone surgery on the muscles
or ligaments of the lower extremities who
had fixed contracture of the lower limb joints
or who exhibited severe athetoid movements
were also excluded.

5

Neuronox and
Botox
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Py A-G5

Clinical
trial

54

Under
18 y/o

university hospitals
because of lower limb
spasticity resulting
from CP.
During the period
from May 2005 to May
2006, all the
ambulatory children
examined in outpatient
consultations in
the spastic diplegia
service, consequential to
periventricular
leukomalacia lesions for
which the examining
doctor recommended an
injection of botulinum
toxin in the lower limbs,
were seen by the senior
doctor in the service
who, after a clinical
examination, confirmed
or rejected the examining
doctor’s recommendation
and suggested injection
sites. The injection site
could be a single or
multiple.

children who had surgery less than three
months previous, and children who were
not re- evaluated one month after their
surgery due to distance concerns.

0

6

Ultrasound
guidance of
the botulinum
toxin injection

OUTCOMES MEASURED
Outcomes measured were those of patient-oriented evidence that matters (POEMS). The
articles all measured outcomes in different ways. Kim and et al and Py and et al, measured
outcomes on the Gross Motor Function measure scale. Carraro and et al measured the outcomes
by a checklist given to the patient’s parents that measured the adverse effects of the treatment.
The outcomes measured were the number of adverse effects.
RESULTS
Two randomized, controlled trials, and one clinical trial were analyzed in this review.
Each study compared the effectiveness of different versions of botulinum toxin serotype A in
children under the age of 18 with lower limb spasticity due to cerebral palsy.
The study done by Py at el was done to show the effectiveness of Botox (onabotulinum
toxin).8 The study included all ambulatory children examined in outpatient consultations in the
spastic diplegia service, from May 2005 to May 2006.8There were 54 children under 18 with
diplegia spastic gait cerebral palsy that participated in the study.8 In order to determine the
injection site of each individual, every child had a visual gait examination and a functional
evaluation done using the Gross Motor Function Measure.8 The product used was Botox
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produced by Allergan Labatory.8The dose was between 5 and 6 UI/kg, according to the marketing
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recommendation for each different muscle.8The dilution of 100 units, was carried out in 1 to 2 ml
of 0.09% physiological serum, with a minimal volume of 0.3mL per injection.8 Of the 54 children
given Botox injections in their lower limbs, 85% of them were evaluated with the GMFM before
and after the injections.8The remaining 15% either had difficulty understanding the instructions or
were opposed to treatment during the procedure.8 Only one undesirable effect was reported by the
patients.8 The overall clinical effectiveness was good in 51% of the children.8The clinical
improvement was better in cases of injections to the hamstring muscle (57%) and/or the
gastrocnemius muscle 57%.These findings show a significant p-value of 0.04.8 The best clinical
improvement was in children under 6 (53%) and over 12.8The effectiveness of the treatment all
increased with increased doses.8 Patients injected with over 0.8IU/kg per muscle was statically
significantly better than injection doses of under 0.8 UI/kg per muscle, the p-value was < 0.05.8
Overall there was a 24% improvement of the GMFM scores in the children treated.8
In the study by Carraro et al6 there were 35 patients recruited and the study was
performed at an institute for rehabilitation and treatment.6 All patients completed the study and
they were all treated by the same physician.6 All the patients had the diagnosis of spastic
diplegia, hemiplegia, or quadriplegia due to cerebral palsy, as verified by history,
clinical/instrumental examination and neuroimaging findings. All the participants were between
the ages of three and eighteen.6 All the participants in the study had clinical indication to have
treatment with BTX-A in the gastrocnemius muscle.6The participants were randomized to either
the study group (incobotulinum toxin A) or the control group (onabotulinum toxin A). Both of
the groups were injected with 5units/kg on the gastrocnemius (medialis and lateralis) muscles
with a clinical conversion ratio of 1:1 for onabotulinum toxin A and incobotulinum toxin A.6
The study group had a total of 17 participants, and the control group had 18 participants.6 The
two groups were well balanced regarding demographics.6 All adverse events were recorded by
the patient’s parents in the form of a checklist at baseline, 48hours after procedure, 10 days
after, and 3 months after.6 The checklist had the most common side effects listed such as fever,
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fatigue, general and local muscle pain, diarrhea, ecchymosis.6 The form also had a blank area
for parents to add any additional side effects that their child experienced.6The adverse effects
were define as “severe” if they were fatal or life-threatening or if they resulted in functional
disability or hospitalizations of the patient.6The adverse effect was termed “local” if they were
confined to the site of the injection.6 Throughout the study there were no severe adverse effects
noted by any of the parents of the participants. The most common “local adverse effect was
fatigue among the study and control group.6 Table 2 demonstrates the statistical information
from the study.
Table 2:Frequency of local adverse events6
Within

Within

Within

the first

the first

the first

48hours

10 days

At Least

Study

Control

one local

group

group

6

7

P values

3 months

Study

Control

group

group

8

6

P values

Study

Control

group

group

0

3

P values

adverse
event

0.56

0.72

0.11

As shown by the results in the table 2, the study group (incobotulinum toxin A) and the control
group (onabotulinum toxin A) had similar numbers of adverse effects with slightly less adverse
effects within the study group overall.
The study done by Kim et al, included 127 total children with cerebral palsy, who
presented at three university hospitals with lower limb spasticity.7 The 127 children were then
assessed for eligibility and 119 were eligible.7 The study was done to access the difference of
adverse events and effectiveness of Neuronox compared with Botox for the treatment of lower
limb spasticity in cerebral palsy.7The mean age of the participants was 4.33 years old, and the
study had 43 females and 76 males.7Participants were randomly assigned to a treatment group.
60 patients were treated with Neuronox and 59 with Botox.7 Each group received the treatment
in the calf muscles at a dose of 4U/kg for those with hemiplegia (40) and 6U/kg of those patients
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with diplegia (79).7 All participants were treated by experienced physicians.7Assessments were
performed at baseline (V1), and a 4(V2), 12(V3), and 24(V4) weeks.7The outcomes were
measured by using the Gross Motor Function Measure 88 (GMFM-88), and was measured at
baseline and every other interval.7 After the treatments the GMFM scores increased significant
at all follow up visits.7 The Neuronox group showed a mean increases of 2.14 at V2, 3.77 at V3,
and 4.76 at V4.7 The botox group showed mean increases of 2.65 at V2, 5.25 at V3, and 6.63 at
V4.7 There was no significant difference in the change in the GMFM scores between the
treatment groups at V2, p=0.41.7 At V3 and V4, Botox showed a larger increase in the GMFM
score than the Neuronox group , p=0.03.7 The frequency of adverse events was not significantly
different between the two groups. The 119 participants that underwent the original evaluation,
101 completed the study without violation of protocol.7 Eight individuals in the Neuronox group
were excluded after the intervention, one due to adverse events, two retracted their consent,
three didn’t attend the scheduled follow up, and two were classified as protocol violators.7Six
individuals in the Botox group were excluded after the intervention, one was excluded because
of an adverse outcome, four retracted their consent, and one didn’t attend the scheduled follow
up.7Also, two individuals in each group were excluded after the final evaluation because of
violation of study protocol.7 According to the study Neuronox is not inferior to Botox.7
Neuronox is not currently FDA approved in the United States.
DISCUSSION
The study by Py et al, showed that Botox is an effective treatment for diplegia spastic gait cerebral
palsy. The reasoning for the best clinical improvement found in children under six can be explained
by the fact that the fibrotic and retractile phenomena are less significant in younger children,
allowing the effects of the treatment to be noted at a greater extent.8It can also be explained by motor
development being greater in that study population, so when the problematic spasticity is eliminated
there is a more rapid influence in overall function.8 The effectiveness of the treatment was also better
in children over 12, which was more surpsing.8 This could be explained by that fact that many of the
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children over 12 have already had musculotendinous surgical treatment in their lower limbs, which
helped the practitioner target more precisely the muscles to be injected.8 The main limitation of this
study is that it was not a double-blind study, which in turn makes the results less reliable.8Two more
limitations to the study include that the post-evaluation took place at 3 to 4 weeks after the injection,
which could have been too early to see complete results, and the percent of improvement could have
been lower in the patients where the dose of the injection was lower per muscle, due to multiple
muscle injections and the cumulative dose for all participants being 6IU/kg of botox.8

The study by Carraro et al showed that incobotulinum toxin A doesn’t have more
adverse effects and is equally beneficial as onabotulinum toxin A.6 The study did not detect
any important difference in safety between these two formulations of BTX-A for the
treatment of lower limb spasticity in children under 18 with cerebral palsy.6 The study as a
whole produced an increase in adverse events relative to other similar studies.6 Within the
whole cohort at 48 hours, 48.6% of patients experienced an adverse event, 47.8% in the first
ten days and 11.8% in the first three months.6 There were a few limitations to the study. The
first being that there was no placebo group, which means that not all adverse events can be
directly linked to the treatment.6 Another limitation of the study is that the parents were
given an articulated list of adverse events, which could have caused the patients to believe
that a certain symptom was from the treatment only because it was listed on the form.6 The
last limitation of this study was the small sample size that participated in the treatments.6 At
this point, incobotulinum toxin A is not currently being used in the United States for
treatment of spastic gait cerebral palsy but this study does show that it could have a place in
the treatment of this condition in the future.6 Further studies need to be done to confirm the
safety and effectiveness of incobotulinum toxin A.
The study by Kim et al, showed Neuronox to be just as effective as Botox. The study as a
whole showed improvement in all children treated in both treatment groups for lower limb spasticity
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from cerebral palsy.7The results of this study are similar to those of previous studies done on Botox.7
The study had a few notable limitations that could have altered the results. One limitation was that
the study was not controlled with a placebo group, which is necessary in order to show the net effect
of the drug.7 Another limitation of the study was that the protocol did not apply variable doses of
either treatments.7 According to the severity of each patient’s spasticity, different doses would
produce more optimal outcomes.7The dose of 4U/Kg could have been insufficient in some cases.7
This study was the first well designed, strictly conducted phase III clinical trail to validate the
effectiveness of Neuronox for lower limb spasticity in cerebral palsy.7The results of this study are
expected to provide physicians with more choices for the treatment of spasticity in cerebral palsy in
the future.7
CONCLUSION
The trials analyzed in this EBM review showed that the different types of botulinum toxin
A all showed significant improvement in the treatment of lower limb spasticity from cerebral
palsy.6,7,8, The study Carraro et al showed that incobotulinum toxin A (Xeomin) was just as
effective for the treatment of spasticity for cerebral palsy, as onabotulinum toxin A(Botox).6 The
study by Kim et al, showed the Neuronox was just as effective as Botox.7 Lastly, the study by Py
et al, provided clear evidence that onabotulinum toxin A (Botox), was even an effective treatment
of spastic gait in cerebral palsy in the first place.8
Future study is warranted to definitively evaluate the efficacy of different types of
botulinum toxin A in the treatment of lower limb spasticity in cerebral palsy. All of the
aforementioned studies have a small population size and various limitations that reduce the
significance of the results. Additional studies should include a larger population and should be
double-bind trials to make the results more reliable. This treatment should be continually
investigated because it could change the treatment options for children with issues of lower
limb spasticity from cerebral palsy.
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